Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Intellia Therapeutics (NTLA – Research Report), Cano Health (CANO – Research Report) and Ultragenyx Pharmaceutical (RARE – Research Report).
Intellia Therapeutics (NTLA)
Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Intellia Therapeutics today and set a price target of $94.00. The company’s shares closed last Friday at $24.79, close to its 52-week low of $22.81.
According to TipRanks.com, Livshits is a 5-star analyst with an average return of
Currently, the analyst consensus on Intellia Therapeutics is a Strong Buy with an average price target of $68.42, which is a 174.1% upside from current levels. In a report issued on November 2, Bank of America Securities also maintained a Buy rating on the stock with a $84.00 price target.
See today’s best-performing stocks on TipRanks >>
Cano Health (CANO)
Truist Financial analyst Jailendra Singh maintained a Hold rating on Cano Health yesterday and set a price target of $5.00. The company’s shares closed last Friday at $7.37.
According to TipRanks.com, Singh is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Cano Health has an analyst consensus of Hold, with a price target consensus of $2.79, which is a -66.1% downside from current levels. In a report issued on November 7, UBS also maintained a Hold rating on the stock with a $12.00 price target.
Ultragenyx Pharmaceutical (RARE)
Truist Financial analyst Joon Lee maintained a Buy rating on Ultragenyx Pharmaceutical today and set a price target of $140.00. The company’s shares closed last Thursday at $34.95, close to its 52-week low of $31.52.
According to TipRanks.com, Lee is a 4-star analyst with an average return of
Ultragenyx Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $97.10, which is a 164.7% upside from current levels. In a report issued on November 2, TD Cowen also maintained a Buy rating on the stock with a $59.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NTLA:
- Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
- Intellia Therapeutics reports Q3 EPS ($1.38), consensus ($1.50)
- Intellia Therapeutics Inc (NTLA) Q3 Earnings Cheat Sheet
- Intellia Therapeutics announces new interim data on NTLA-2001
- Cathie Wood’s ARK Investment bought 284K shares of Intellia Therapeutics today
